EGFR and non-small cell lung carcinoma: Of note, in the IMpower-150 study (n = 124 EGFR-mutant NSCLC patients), atezolizumab plus bevacizumab and chemotherapy (ABCP; n = 34) yielded a higher ORR (71 vs. 42%), DOR (11.1 vs. 4.7 months), PFS (10.2 vs. 6.9 months; HR, 0.61; 95% CI, 0.36–1.03), and OS (not evaluable [NE] vs. 18.7 months; HR, 0.61; 95% CI, 0.29–1.28) compared to bevacizumab plus chemotherapy (BCP; n = 45) (151).